GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioMarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Cyclically Adjusted PS Ratio

BioMarin Pharmaceutical (BSP:B1MR34) Cyclically Adjusted PS Ratio : 4.65 (As of Jul. 06, 2025)


View and export this data going back to 2020. Start your Free Trial

What is BioMarin Pharmaceutical Cyclically Adjusted PS Ratio?

As of today (2025-07-06), BioMarin Pharmaceutical's current share price is R$157.44. BioMarin Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was R$33.87. BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio for today is 4.65.

The historical rank and industry rank for BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio or its related term are showing as below:

BSP:B1MR34' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.8   Med: 12.68   Max: 44.11
Current: 5.01

During the past years, BioMarin Pharmaceutical's highest Cyclically Adjusted PS Ratio was 44.11. The lowest was 4.80. And the median was 12.68.

BSP:B1MR34's Cyclically Adjusted PS Ratio is ranked better than
53.47% of 490 companies
in the Biotechnology industry
Industry Median: 5.685 vs BSP:B1MR34: 5.01

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioMarin Pharmaceutical's adjusted revenue per share data for the three months ended in Mar. 2025 was R$10.919. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is R$33.87 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


BioMarin Pharmaceutical Cyclically Adjusted PS Ratio Historical Data

The historical data trend for BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMarin Pharmaceutical Cyclically Adjusted PS Ratio Chart

BioMarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.73 11.16 11.49 9.59 5.91

BioMarin Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.38 7.72 6.43 5.91 6.16

Competitive Comparison of BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio falls into.


;
;

BioMarin Pharmaceutical Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=157.44/33.87
=4.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, BioMarin Pharmaceutical's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=10.919/134.9266*134.9266
=10.919

Current CPI (Mar. 2025) = 134.9266.

BioMarin Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 2.426 100.684 3.251
201509 2.530 100.392 3.400
201512 2.744 99.792 3.710
201603 2.710 100.470 3.639
201606 3.160 101.688 4.193
201609 2.715 101.861 3.596
201612 2.922 101.863 3.870
201703 2.750 102.862 3.607
201706 3.000 103.349 3.917
201709 2.989 104.136 3.873
201712 3.364 104.011 4.364
201803 3.476 105.290 4.454
201806 3.975 106.317 5.045
201809 4.534 106.507 5.744
201812 3.837 105.998 4.884
201903 4.317 107.251 5.431
201906 4.175 108.070 5.213
201909 5.108 108.329 6.362
201912 5.195 108.420 6.465
202003 6.553 108.902 8.119
202006 6.165 108.767 7.648
202009 6.512 109.815 8.001
202012 6.396 109.897 7.853
202103 7.428 111.754 8.968
202106 6.803 114.631 8.007
202109 5.889 115.734 6.866
202112 6.929 117.630 7.948
202203 6.631 121.301 7.376
202206 7.187 125.017 7.757
202209 7.139 125.227 7.692
202212 7.578 125.222 8.165
202303 7.991 127.348 8.467
202306 7.409 128.729 7.766
202309 7.509 129.860 7.802
202312 8.399 129.419 8.756
202403 8.108 131.776 8.302
202406 9.563 132.554 9.734
202409 10.474 133.029 10.623
202412 11.585 133.157 11.739
202503 10.919 134.927 10.919

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioMarin Pharmaceutical  (BSP:B1MR34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BioMarin Pharmaceutical Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioMarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

BioMarin Pharmaceutical Headlines

No Headlines